Skip to main content
. 2022 Feb 14;13:814291. doi: 10.3389/fgene.2022.814291

FIGURE 5.

FIGURE 5

Identification of key lncRNA and experimental verification of CTD-2288O8.1 (1). (A) CCK-8 assay showing A2780-DDP (IC50 = 12.104 μg/ml) and SKOV3-DDP (IC50 = 5.868 μg/ml) have the stronger cisplatin resistance than corresponding parent cell lines A2780 (IC50 = 1.1 μg/ml) and SKOV3 (IC50 = 1.096 μg/ml). (B) qRT-PCR showing relative RNA level expression of CTD-2288O8.1 in cisplatin-resistant cells (A2780-DDP and SKOV3-DDP) and parent cells (A2780 and SKOV3). (C) qRT-PCR showing the RNA level expression of CTD-2288O8.1 in primary and recurrent tissues of ovarian cancer. (D) Relative expression of CTD-2288O8.1 in a panel of OC cell lines (SKOV3, A2780, OVCAR3, and HO8910). (E) Transfection efficiency of si-CTD-2288O8.1 and CTD-2288O8.1 overexpression plasmid in A2780 and SKOV3 cell lines (qRT-PCR). (F) CCK-8 assay showing CTD-2288O8.1 silencing suppressed the cisplatin-resistance in A2780 (left). CTD-2288O8.1 overexpression increased the cisplatin-resistance in SKOV3 (right). (G) CCK-8 assay showing CTD-2288O8.1 silencing suppressed the proliferation of A2780 (left) and CTD-2288O8.1 overexpression promoted the proliferation of SKOV3 (right). Error bars represent within-group deviation. si-NC, control siRNA; empty vector, control plasmid (pEX-3); OD, optical density. *p-value < 0.05, **p-value < 0.01, and ****p-value < 0.0001.